Clinical Trial

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-14
notable Enrollment reduced: 56 -> 9 participants 2026-08-14
Trial Details
NCT Number NCT06007937
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Eli Lilly and Company
Conditions Non Small Cell Lung Cancer, Metastatic, Recurrent
Enrollment 9 participants
Start Date 2023-08-17
Primary Completion 2028-08-17 (estimated)
Study Completion 2028-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-13